| Literature DB >> 34084767 |
Antonio Junior Lepedda1, Gabriele Nieddu1, Marilena Formato1, Matthew Brandon Baker2, Julia Fernández-Pérez2, Lorenzo Moroni2.
Abstract
Cardiovascular diseases represent the number one cause of death globally, with atherosclerosis a major contributor. Despite the clinical need for functional arterial substitutes, success has been limited to arterial replacements of large-caliber vessels (diameter > 6 mm), leaving the bulk of demand unmet. In this respect, one of the most challenging goals in tissue engineering is to design a "bioactive" resorbable scaffold, analogous to the natural extracellular matrix (ECM), able to guide the process of vascular tissue regeneration. Besides adequate mechanical properties to sustain the hemodynamic flow forces, scaffold's properties should include biocompatibility, controlled biodegradability with non-toxic products, low inflammatory/thrombotic potential, porosity, and a specific combination of molecular signals allowing vascular cells to attach, proliferate and synthesize their own ECM. Different fabrication methods, such as phase separation, self-assembly and electrospinning are currently used to obtain nanofibrous scaffolds with a well-organized architecture and mechanical properties suitable for vascular tissue regeneration. However, several studies have shown that naked scaffolds, although fabricated with biocompatible polymers, represent a poor substrate to be populated by vascular cells. In this respect, surface functionalization with bioactive natural molecules, such as collagen, elastin, fibrinogen, silk fibroin, alginate, chitosan, dextran, glycosaminoglycans (GAGs), and growth factors has proven to be effective. GAGs are complex anionic unbranched heteropolysaccharides that represent major structural and functional ECM components of connective tissues. GAGs are very heterogeneous in terms of type of repeating disaccharide unit, relative molecular mass, charge density, degree and pattern of sulfation, degree of epimerization and physicochemical properties. These molecules participate in a number of vascular events such as the regulation of vascular permeability, lipid metabolism, hemostasis, and thrombosis, but also interact with vascular cells, growth factors, and cytokines to modulate cell adhesion, migration, and proliferation. The primary goal of this review is to perform a critical analysis of the last twenty-years of literature in which GAGs have been used as molecular cues, able to guide the processes leading to correct endothelialization and neo-artery formation, as well as to provide readers with an overall picture of their potential as functional molecules for small-diameter vascular regeneration.Entities:
Keywords: glycosaminoglycans; scaffolds; tissue engineering; vascular disease; vascular regeneration
Year: 2021 PMID: 34084767 PMCID: PMC8167061 DOI: 10.3389/fchem.2021.680836
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
FIGURE 1Structures of the repeating disaccharide units representative of the six GAGs classes [modified from (Vynios et al., 2002)]. Both DS and HS/Hep are co-polymers of two types of disaccharide repeats where glucuronate is variably substituted by its carbon-5 epimer iduronate. Hep has both a higher degree of sulfation and epimerization than HS. Except for HA, sulfation may occur in several positions, thus giving these glycans a characteristic high negative charge. Saccharides are reported as chair conformations. Configurations of the O-glycosidic bonds are reported in red (within disaccharide units) and in green (between adjacent disaccharide units). R1 = SO3 −; R2 = COCH3/SO3 −.
FIGURE 2Schematic representation of the main vascular PGs according to their localization. Three main classes are reported: cell-associated, pericellular, and extracellular proteoglycans. Protein moieties are shown as orange backbones (versican G1 domain is highlighted in red).
FIGURE 3Main methods for the fabrication of small caliber vascular grafts.
FIGURE 4Fabrication method of porous tubular scaffolds from elastin-like recombinamers by salt leaching/gas foaming technique and electrospinning [modified from (Fernández-Colino et al., 2019)].
FIGURE 5Representative scanning electron microscopy (SEM) images of random (mandrel speed = 500 rpm) and aligned (mandrel speed = 4000 rpm) PCL fibers (panels A and B, respectively) [modified from (Idini et al., 2019)].
FIGURE 63D bioprinting of vasculature using core-shell approach, where endothelial cells are suspended in an alginate-ECM bioink as the shell and the core is a fugitive bioink composed of Pluronic F127 containing Ca2+ ions (CPF127) [modified from (Gao et al., 2018)].
FIGURE 7A thread (left) and a woven vessel (right) made from human Cell-assembled Extracellular Matrix [modified from (L’Heureux, 2020)].
FIGURE 8Hematoxylin and eosin staining of native bovine pericardium (A) and decellularized bovine pericardium before (B) and after (C) 7 days of culture with bovine fibroblasts. Magnification ×20 [from (Cigliano et al., 2012)].
Hyaluronan-based vascular constructs for small-caliber artery grafting.
| References | Scaffold material and manufacturing method | Development level | Main findings |
|---|---|---|---|
|
| HYAFF-11 non-woven scaffolds: Unpressed and pressed felts |
| Pressed felts: Complete endothelialization after 20 days; deposition of a subendothelial matrix containing laminin, fibronectin, type IV and type VIII collagen |
|
| HYAFF-11 non-woven meshes as sheets or 3D tubular scaffolds obtained by wrapping the former around a cylindrical mandrel after 7 days of culture |
| Tubular scaffolds highly cellularized within the wall thickness but with lower mechanical resistance than porcine coronary arteries |
|
| HYAFF-11 tubes obtained by coagulation of a HYAFF-11/dmso solution around a cylindrical bar (2 mm diameter) in an ethanol bath |
| Complete regeneration of a newly formed vascular tube at day 90; no signs of inflammation, stenoses or aneurysms; all animals survived during the 90 days follow up |
|
| HYAFF-11 tubes obtained by coagulation of a HYAFF-11/dmso solution around a cylindrical bar (2 mm diameter) in an ethanol bath |
| Complete endothelialization of the tube’s luminal surface; complete vascular wall regeneration 15 days after surgery; complete degradation of the construct 4 months after implantation |
|
| HYAFF-11 non-woven meshes as sheets or 3D tubular scaffolds obtained by wrapping the former around a cylindrical mandrel after 7 days of culture in a medium supplemented with 50 mg/ml of sodium ascorbate |
| Sodium ascorbate improved cell proliferation and ECM synthesis as well as mechanical properties of the vascular construct |
|
| HYAFF-11 tubes obtained by coagulation of a HYAFF-11/dmso solution around a cylindrical bar (4 mm diameter) in an ethanol bath |
| Confirmation of the potential of hyaluronan-based graft to guide the development of a well-functioning neoartery with organized layers of elastin fibers, 5 months post-surgery; 3 cases of partial or complete occlusion by intimal hyperplasia and graft thrombosis |
|
| HYAFF-11 tubes obtained by coagulation of a HYAFF-11/dmso solution around a cylindrical bar (2 mm diameter) in an ethanol bath |
| Complete vein wall regeneration at day 30; complete reabsorption of the graft 4 months after surgery |
|
| HYAFF-11 patches (0.1 mm thickness) |
| Almost complete degradation of the scaffold and replacement by a neoartery wall composed of endothelial cells, smooth muscle cells, collagen, and elastin fibers organized in layers, after 16 weeks |
|
| Electropun aligned nanofibrous PCL scaffolds functionalized with LMW-HA by using EDC/NHS following aminolysis with 1,6-hexanediamine |
| The combination of aligned PCL fibers and LMW-HA promotes and guides the formation of a polarized functional endothelium |
|
| Human-like collagen/hyaluronic acid (HA MW 100,000–110,000 Da) composite disks obtained, at different HLC/HA ratios, by cross-linking with glutaraldehyde followed by freeze-drying |
| Among the different composites assessed, the 10/1 HLC/HA composite showed higher porosity, better mechanical properties and excellent biocompatibility |
|
| Highly aligned PLLA/HA (HA MW > 400 KDa) core-shell nanofibers (jet coaxial-electrospinning) crosslinked with glutaraldehyde and hydrochloric acid |
| Synergistic effect of nanotopographical and biochemical cues in promoting scaffold population by vSMCs and synthesis of elastin. Circumferentially aligned HA/PLLA nanofibers were effective in maintaining patency and promoting vascular regeneration during 6 weeks after surgery |
|
| Electrospun scaffolds of type I collagen glycosilated with HA oligomers by reductive amination (using sodium cyanoborohydride), crosslinked with glutaraldehyde |
| Endothelial cells proliferation was promoted by HA oligomers and inhibited by high molecular weight HA. The scaffolds had no detectable degree of hemolysis and coagulation |
|
| Electrospun scaffolds of type I collagen glycosilated with HA oligomers using EDC/NHS, crosslinked with glutaraldehyde |
| Potential of the collagen–HA electrospun nanofibers as the vascular inner-layer scaffold |
HYAFF-11: 100% benzyl ester hyaluronan-based biomaterial produced by Fidia Advanced Biopolymers (Abano Terme, Italy).
Heparin-functionalized vascular scaffolds for small-caliber artery grafting. Acellular tissue engineered vessels (A-TEVs) (highlighted in gray).
| References | Scaffold material and manufacturing method | Development level | Main findings |
|---|---|---|---|
|
| Decellularized porcine carotid artery covalently linked with heparin using EDC |
| Excellent mechanical properties, antithrombogenicity, and tissue compatibility; effective scaffold population by both smooth muscle cells and endothelial cells within 2 months post-implantation |
|
| Poly(carbonate-urea)urethane graft (MyoLink™) functionalized with arginine-glycine-aspartate (RGD) or/and hep |
| RGD/Hep functionalization improved cell retention and metabolic activity with respect to native MyoLink |
|
| Heparinized decellularized porcine carotid artery |
| Sufficient mechanical properties and successful replacement by the host cells in 18 weeks |
|
| Decellularized porcine carotid artery, covalently linked with hep using EDC, incubated with basic fibroblast growth factor |
| bFGF coating on the Hep-bound decellularized grafts significantly increases attachment and proliferation of the seeded cells that remain stable under perfusion conditions |
|
| Decellularized canine carotid artery coated with hep (EDC/NHS) and coated with vascular endothelial growth factor |
| Complete endothelium regeneration and higher patency rate than the nonmodified scaffold after 6 months implantation |
|
| Electrospun PLLA/Hep scaffolds with an outer layer of PCL by FDM |
| Drug delivery system with a microenvironment able to induce endothelial differentiation |
|
| Heparinized silk-based construct |
| Stimulation of elastogenesis |
|
| FGF2-loaded electrospun Hep–PCL vascular scaffolds |
|
|
|
| Electrospun microfibres scaffolds of PLLA-PCL blends functionalized with Hep (EDC/NHS) and heparin-bound stromal cell-derived factor-1α (SDF-1α) |
| Effective recruitment of endothelial progenitor cells (EPCs) to the luminal surface of the grafts, which differentiated into endothelial cells, and of smooth muscle progenitor cells, which differentiated into smooth muscle cells |
|
| Poly (glycerol sebacate) core surrounded by an electrospun PCL sheath, coated with heparin |
| Three months after implantation, the neoarteries resembled native arteries in the following aspects: Regular, strong and synchronous pulsation; a confluent endothelium and contractile smooth muscle layers; expression of elastin, collagen and glycosaminoglycan; and tough and compliant mechanical properties |
|
| Electrospun Hep–PCL nonwoven tubular scaffolds |
| Low protein absorption and good cell biocompatibility; presence of endothelial cells monolayer and extracellular matrix 1 month after surgery |
|
| Decellularized canine carotid artery coated with Hep (EDC/NHS) cultured with canine endothelial progenitor cells in a custom-made bioreactor |
| Excellent biocompatibility and high patency rate at 3 months post-implantation |
|
| Polyurethane-collagen/Hep-conjugated polycaprolactone double-layer small-diameter vascular graft |
| Good biocompatibility and high patency at 8 weeks after surgery |
|
| Hep-bound P(LLA-CL)/P(LLA-CL) double-layer small-diameter vascular graft |
| Biomechanical properties similar to those of canine femoral arteries; satisfactory endothelialization |
|
| Hep-bound P(LLA-CL)/P(LLA-CL) double-layer small-diameter vascular graft pre-endothelialized |
| The pre-endothelialization has better mechanical properties and cellular compatibility than the simple heparinization |
|
| Heparinized POC-modified ePTFE grafts |
| Reduced platelet adhesion and inhibition of blood clotting; support for endothelial cells adhesion, viability, proliferation, NO production, and expression of specific markers. Smooth muscle cells increased expression of |
|
| Electrospun PHEA-eda-g-pla/pcl scaffold functionalized with Hep (EDC/NHS) |
| Effective retention of bFGF and promotion of ecs growth |
|
| Co-electrospun PCL/Chitosan hybrid grafts functionalized with Hep (ionic bonding with chitosan) |
| Promotion of HUVECs growth and moderate inhibition of hSMCs proliferation; optimal anti-thrombogenic effects and enhanced |
|
| Small-diameter tubular PLLA/PLCL scaffolds obtained by thermally induced phase separation functionalized with Hep (EDC/NHS) |
| 60% PLCL promising scaffold for engineering small-diameter blood vessel in terms of biomechanical properties; heparinization provided higher hydrophilicity, lower protein adsorption, and better |
|
| Decellularized rat aortas infused with poly(1,8 octanediol citrate) (POC) and functionalized with Hep (EDC/NHS) |
| Reduced platelet adhesion and inhibited whole blood clotting; support for endothelial cell adhesion |
|
| Click-coated, heparinized, decellularized pig aortic graft |
| Reduced platelet adhesion and thrombogenicity; supported endothelial cell adhesion and proliferation |
|
| Electrospun poly( |
| Effective antithrombotic potential and promotion of endothelial progenitor cells growth |
|
| Acellular tissue engineered vessel based on small intestinal submucosa functionalized sequentially with Hep (EDC/NHS) and VEGF |
| Complete endothelialization and formation of a medial layer of circumferentially aligned smooth muscle cells; high elastin and collagen content; impressive mechanical properties and vascular contractility comparable to native arteries |
|
| Electrospun poly ( |
| Effective host cell infiltration, neotissue formation, collagen and elastin deposition |
|
| Coaxially electrospun PCL/collagen core–shell nanofibrous scaffolds crosslinked by genipin and functionalized with Hep |
| Good biocompatibility; support for vascular cells attachment and growth on its surface, and for the infiltration of SMCs inside |
|
| Co-electrospun PCL/gelatin/polyvinyl alcohol functionalized with Hep |
| Good mechanical properties; antithrombogenic; enhanced growth of endothelial cells |
|
| Electrospun PCL/PCL2K-N3 functionalized with alkynyl-Hep |
| Reduced platelet adhesion; inhibition of VSMCs proliferation in a dose-dependent manner and promotion of the transition from synthetic phenotype to contractile one; moderate Hep density induces the formation of a confluent layer of contractile smooth muscle cells |
|
| Decellularized rat aortas coated with electrospun PCL, with a heparinized luminal surface |
| Satisfactory patency for up to 6 weeks; successful prevention of the occurrence of vasodilation and aneurysm formation after transplantation and reduced inflammatory cells infiltration |
|
| Electropun fibrous scaffolds of elastic poly (ester urethane)urea with disulfide and amino groups (PUSN) orthogonally functionalized with Hep (EDC/NHS) and endothelial progenitor cells (EPC) recruiting peptide (TPS) |
| Reduced platelet deposition and improved EPCs proliferation |
|
| Decellularized rat aorta functionalized with CBP-Hep (CBP, collagen binding peptide) |
| Reduced platelet binding and whole blood clotting; stabilization of long-term endothelial cell attachment to the lumen of ECM-derived vascular conduits |
|
| Polycarbonate polyurethane scaffold treated with NH3 plasma and functionalized with Hep (EDC/NHS) |
| Improved |
|
| Composite silk-based vascular scaffold functionalized with Hep using hydroxy-iron complexes (HICs) as linkers |
| Good biomechanical properties (flexibility, suture retention strength, burst pressure, and compliance); sustained antithrombogenicity, cytocompatibility and nonhemolytic properties |
|
| Electrospun poly- |
| Plasma treatment resulted in significantly higher initial hep density and higher Hep stability on PLCL microfibers than fmoc-peg-diamine treatment as well as better mechanical properties; Hep coating with both methods promoted cell infiltration |
|
| Electrospun polycaprolactone scaffolds functionalized with Hep (EDC/NHS) and absorbed VEGF |
| Mechanical properties compatible with the native arteries; antithrombogenic properties and increased EPC proliferation, favoring the formation of the endothelial layer |
|
| Electrospun polycarbonate-urethane (PCU) nanofibrous grafts treated with plasma to conjugate Hep |
| High patency rate at 2 and 4 weeks; complete endothelialization of the luminal surface with an aligned, well-organized monolayer of endothelial cells, extensive graft integration in terms of vascularization and cell infiltration from the surrounding tissue |
|
| Electrospun PLLA scaffold blended with low MW PCL or low MW PLLA functionalized with Hep (EDC/NHS) and absorbed VEGF |
| Enhanced endothelium formation and the overall patency of vascular grafts; increased cell infiltration into the electrospun grafts and production of collagen and elastin fibers within the graft wall |
|
| PCL functionalized with Hep–tyramine polymer and a potent anti-neointimal drug (mitogen activated protein kinase II inhibitory peptide; MK2i) |
| Enhanced blood compatibility with significantly reduced protein absorption and platelet adhesion; significant inhibitory effects on VSMC migration associated with intimal hyperplasia |
|
| Coaxial-elctrospun scaffolds of poly ( |
| High attachment efficiency and proliferation; high short-term patency |
|
| Electrospun scaffolds from blends of poly ( |
| Inhibition of platelet adhesion and of hemolysis; adhesion and proliferation of human adipose-derived stem cells; antimicrobial activities |
|
| Electrospun PCL scaffolds aminolyzed and functionalized with hep (EDC/NHS) |
| Induction of SMCs penetration into the scaffold and differentiation into contractile phenotype |
|
| Rat aorta decellularized vascular graft functionalized with antioxidant poly(1, 8-octamethylene-citrate-co-cysteine) (POCC) and Hep |
| Grafts displayed antioxidant activity, patency, and minimal intramural cell infiltration with varying degrees of calcification (inversely related to the antioxidant capacity), at 3 months post-surgery |
|
| Dual layer conduit consisting of collagen I-hyaluronic acid (external layer) and collagen I-Hep (inner layer) crosslinked with EDC |
| Satisfactory mechanical performance and support for cells adhesion, proliferation and elongation |
|
| Electrospun PCL/keratin nanofibrous mats functionalized with Hep (EDC/NHS) |
| Effective antithrombotic potential; induction of NO release, which enhance endothelial cell growth and inhibits smooth muscle cell proliferation and platelet adhesion |
|
| Electrospun PCL scaffolds functionalized with Hep (EDC/NHS) |
| All implanted grafts were patent during the 6 months post-surgery and showed a well-organized neo-tissue with endothelium formation, smooth muscle regeneration, and extracellular matrix formation |
|
| Bilayer heparinized vascular graft: Inner layer made by co-electrospinning of PCL and gelatin; outer layer fabricated by freeze-drying of gelatin hydrogel; Hep blending in gelatin solution and emulsion of PCL fibers |
| Improved endothelial cell attachment and decreased amount of activated platelets; mechanical properties similar to the coronary artery |
|
| Decellularized porcine carotid arteries functionalized with Hep (EDC/NHS) |
| Improved mechanical properties, reduced inflammatory reaction and slow degradation time; effective inhibition of thrombogenesis |
|
| Two-layer composite vascular graft: Inner layer made of poly(lactic-co-glycolic acid)/Collagen nanofibers modified by mesoporous silica nanoparticles and grafted with polyethylene glycol and Hep; outer layer made of polyurethane nanofibers |
| Good blood compatibility; absence of inflammatory reaction; regeneration of endothelial cells monolayer and smooth muscle media layer |
|
| Acellular tissue engineered vessel based on small intestinal submucosa functionalized sequentially with Hep (EDC/NHS) and VEGF |
| Well-demarcated luminal and medial layers resembling those of native arteries; anti-inflammatory action of VEGF on infiltrating monocytes |
|
| PLLA/PLGA/PLCL composite scaffolds fabricated by using TIPS, functionalized with Hep (EDC/NHS) and stromal cell-derived factor-1 alpha (SDF-1α) |
| Enhanced anticoagulation of vascular scaffold; acceleration of endothelialization and inhibition of hVSMCs proliferation |
|
| Double-layer vascular scaffold: Inner layer made of electrospun end-group heparinized PCL nano- and microfibers; outer layer made of electrospun PCL |
| Patency, endothelialization and fine revascularization were observed at 2 months post-implantation; aneurysmal dilatation of the outer layer; no signs of calcification |
|
| Electrospun PCL scaffolds functionalized with multiple layers of vascular endothelial growth factor (VEGF) and Hep (repeated electrostatic adsorption self-assembly) crosslinked by genipin |
| Early and full release of VEGF to promote rapid endothelialization; gradual but sustained release of Hep for long-term anticoagulation and antithrombogenicity; improved cell viability and rapid endothelialization |
|
| Electrospun PCL/gelatin hybrid vascular grafts functionalized with Hep (EDC/NHS) |
| Promotion of endothelialization and regulation of smooth muscle regeneration; inhibition of thrombosis |
|
| Electrospun PCL scaffolds functionalized with multiple layers of vascular endothelial growth factor (VEGF), polylysine, and Hep (repeated electrostatic adsorption self-assembly) nanoparticles crosslinked by genipin |
| Successful induction of vascular endothelialization and long-term anticoagulation; long-term release of bioactive factors without burst release |
|
| Acellular tissue engineered vessel based on small intestinal submucosa functionalized sequentially with Hep (EDC/NHS) and VEGF |
| Immobilized VEGF captures blood circulating monocytes that differentiate into mature ECs that align in the direction of flow and produce nitric oxide under high shear stress. Highly prevalent circulating MC contribute directly to the endothelialization of acellular vascular grafts under the right chemical and biomechanical cues |